Clarity and SubjectWell have announced a merger that will combine the two businesses into one of the largest global, full-service patient recruitment platforms, bringing together global scale, scientific rigor, and patient-first design to improve clinical trial access and execution worldwide.
The transaction was led by WindRose Health Investors, which previously acquired SubjectWell in April 2024. Following the merger, the combined organization will operate under the Clariness name.
The companies said the combination is intended to create a leading global patient recruitment platform supported by local, in-market, native speaking teams, with the ability to support global clinical trials in more than 60 countries across North America, South America, Europe, and the Asia Pacific.
Clariness and SubjectWell also highlighted the combined footprint and operating scale of the new organization, citing more than 42,000 randomizations delivered, partnerships with more than 10,000 research sites, and support for more than 400 indications globally. The merged company will offer patient marketing, a large patient database, full-service creative capabilities, and purpose-built technology intended to accelerate clinical trial timelines and improve recruitment performance.
The organizations said the merger will also strengthen patient-centered solutions across the clinical trial lifecycle, with a focus on faster enrollment, improved predictability, and stronger patient retention for patients, sponsors, CROs, and sites.
Fairmount Partners acted as financial advisor to Clariness. Stout served as financial advisor to SubjectWell and WindRose in the transaction.
KEY QUOTES
“The combination of these two businesses under the Clariness brand creates a category-defining patient recruitment platform that is powered by innovation, data, and technology. Clariness’ and SubjectWell’s technology and breadth of capabilities bring much needed speed and efficiency to clinical research, delivering significant value to customers.”
CJ Burnes, Partner, WindRose Health Investors
“Clariness and SubjectWell are both market-leading platforms and together, they will bring unparalleled scale and capabilities to customers. By being able to support clinical trials across any geography and therapeutic area, the new Clariness will accelerate clinical research and expand access to healthcare for patients.”
Kristin Melocik, Principal, WindRose Health Investors
“Clariness and SubjectWell share a common vision and a relentless focus on quality. Together, we are creating a global market leader that delivers greater scale, speed, and consistency for our customers, while prioritizing patient experience and expanding access to clinical trials worldwide.”
Fred Martin, CEO, SubjectWell
“The merged company will set the standard in the patient recruitment market. We are excited to use our combined expertise and technology to efficiently deliver more patients to more clients.”
Stefan Mayer-Eggersmann, CEO, Clariness
